menu

More than 70% lowering of triglycerides with APOC3 RNAi in patients with severe hypertriglyceridemia

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

More than 70% lowering of triglycerides with APOC3 RNAi in patients with severe hypertriglyceridemia

Daniel Gaudet at the ACC24
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    ACC.24 - Daniel Gaudet shares the results of the SHASTA-2 trial. The APOC3 RNAi plozasiran is highly effective and well tolerated in patients with severe hypertriglyceridemia, and demonstrated sustainability in the efficacy through week 48, according to Daniel Gaudet. 

  • Educational information

    This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.

  • Faculty

    Daniel Gaudet, MD, PhD is a clinician-researcher in lipidology and professor of medicine at the Université de Montreal (U de M), in Montreal, QC, Canada.

  • Disclaimer

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    Read our summary of SHASTA-2

    Release date: 9 april 2024

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    ACC.24 - Daniel Gaudet shares the results of the SHASTA-2 trial. The APOC3 RNAi plozasiran is highly effective and well tolerated in patients with severe hypertriglyceridemia, and demonstrated sustainability in the efficacy through week 48, according to Daniel Gaudet. 

  • Educational information

    This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.

  • Faculty

    Daniel Gaudet, MD, PhD is a clinician-researcher in lipidology and professor of medicine at the Université de Montreal (U de M), in Montreal, QC, Canada.

  • Disclaimer

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    Read our summary of SHASTA-2

    Release date: 9 april 2024

Facebook Comments

Schedule30 May 2024